LeMaitre director granted dividend equivalent rights

Q: What did the LMAT Form 4 filed by Bridget A. Ross report?

The Form 4 reports that director Bridget A. Ross acquired several small blocks of dividend equivalent rights on March 26, 2026. These awards are tied to prior restricted stock and performance share unit grants and represent routine equity compensation accruals, not open-market trades.

Q: Are the LMAT dividend equivalent rights in this Form 4 open-market purchases or sales?

They are not open-market purchases or sales. The filing shows grant/award acquisitions of dividend equivalent rights as part of existing equity awards. Each right tracks dividends and is the economic equivalent of one share of common stock, vesting with the underlying units.

Q: What are dividend equivalent rights in the context of LMAT’s equity awards?

Dividend equivalent rights are compensation instruments that mirror the value of dividends on LMAT common stock. According to the filing, each is the economic equivalent of one share and accrues on restricted stock unit and performance share unit awards, vesting proportionately with those underlying grants.

Q: Which prior equity awards generated the LMAT dividend equivalent rights for Bridget A. Ross?

The rights accrued on restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025. The filing notes these dividend equivalents vest in step with each corresponding underlying award.

Q: Does this LMAT Form 4 indicate any change in Bridget A. Ross’s trading behavior?

The Form 4 does not show trading behavior in the open market. All reported entries are coded as grant or award acquisitions of dividend equivalent rights, reflecting normal equity compensation mechanics rather than discretionary buying or selling of LMAT common stock.

LEMAITRE VASCULAR INC director Bridget A. Ross reported compensation-related awards of dividend equivalent rights tied to existing equity grants.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

LEMAITRE VASCULAR INC director Bridget A. Ross reported compensation-related awards of dividend equivalent rights tied to existing equity grants. On March 26, 2026, she acquired several small blocks of dividend equivalent rights, each economically equivalent to one share of common stock and linked to prior restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025. These rights vest proportionately with the underlying awards and reflect routine equity compensation accruals rather than open-market trading.

Insider Trade Summary

Grant/Award: 3.444 shares

Grant/Award 5 txns

Insider Ross Bridget A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Dividend Equivalent Rights	0.3941	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	0.472	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	0.6426	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	0.7276	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights	1.2077	$0.00	$0.00

Holdings After Transaction: Dividend Equivalent Rights — 17.2834 contracts (Direct)

Footnotes (5)

F1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F2. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F4. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

Key Figures

Dividend equivalent rights grant: 0.3941 rights Dividend equivalent rights grant: 0.4720 rights Dividend equivalent rights grant: 0.6426 rights +2 more

5 metrics

Dividend equivalent rights grant 0.3941 rights Grant on March 26, 2026, tied to prior award

Dividend equivalent rights grant 0.4720 rights Grant on March 26, 2026, tied to prior award

Dividend equivalent rights grant 0.6426 rights Grant on March 26, 2026, tied to prior award

Dividend equivalent rights grant 0.7276 rights Grant on March 26, 2026, tied to prior award

Dividend equivalent rights grant 1.2077 rights Grant on March 26, 2026, tied to prior award

Key Terms

Dividend Equivalent Rights, restricted stock unit award, performance share unit award, economic equivalent of one share, +1 more

5 terms

Dividend Equivalent Rights financial

"These dividend equivalent rights accrued on a restricted stock unit award"

Dividend equivalent rights are promises that mirror the cash payments shareholders get from a company’s profits, but they are paid to holders of certain awards (like stock options or restricted stock units) rather than to actual shares. Think of them as a paycheck top‑up that matches dividends while the award is not yet a real stock, and they matter to investors because they add to employee compensation costs and potential share dilution, affecting company profitability and per‑share value.

restricted stock unit award financial

"These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

vest proportionately financial

"and vest proportionately with such award"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the LMAT Form 4 filed by Bridget A. Ross report?

The Form 4 reports that director Bridget A. Ross acquired several small blocks of dividend equivalent rights on March 26, 2026. These awards are tied to prior restricted stock and performance share unit grants and represent routine equity compensation accruals, not open-market trades.

Are the LMAT dividend equivalent rights in this Form 4 open-market purchases or sales?

They are not open-market purchases or sales. The filing shows grant/award acquisitions of dividend equivalent rights as part of existing equity awards. Each right tracks dividends and is the economic equivalent of one share of common stock, vesting with the underlying units.

What are dividend equivalent rights in the context of LMAT’s equity awards?

Dividend equivalent rights are compensation instruments that mirror the value of dividends on LMAT common stock. According to the filing, each is the economic equivalent of one share and accrues on restricted stock unit and performance share unit awards, vesting proportionately with those underlying grants.

Which prior equity awards generated the LMAT dividend equivalent rights for Bridget A. Ross?

The rights accrued on restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025. The filing notes these dividend equivalents vest in step with each corresponding underlying award.

Does this LMAT Form 4 indicate any change in Bridget A. Ross’s trading behavior?

The Form 4 does not show trading behavior in the open market. All reported entries are coded as grant or award acquisitions of dividend equivalent rights, reflecting normal equity compensation mechanics rather than discretionary buying or selling of LMAT common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/30/2026 - 06:03 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ross Bridget A

(Last)

(First)

(Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON

MASSACHUSETTS

01803

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Dividend Equivalent Rights	⁽¹⁾	03/26/2026		A		0.3941		⁽¹⁾	⁽¹⁾	Common Stock	0.3941	$0	4.6016	D
Dividend Equivalent Rights	⁽²⁾	03/26/2026		A		0.472		⁽²⁾	⁽²⁾	Common Stock	0.472	$0	4.3113	D
Dividend Equivalent Rights	⁽³⁾	03/26/2026		A		0.6426		⁽³⁾	⁽³⁾	Common Stock	0.6426	$0	3.5389	D
Dividend Equivalent Rights	⁽⁴⁾	03/26/2026		A		0.7276		⁽⁴⁾	⁽⁴⁾	Common Stock	0.7276	$0	3.6239	D
Dividend Equivalent Rights	⁽⁵⁾	03/26/2026		A		1.2077		⁽⁵⁾	⁽⁵⁾	Common Stock	1.2077	$0	1.2077	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR